# HealthMatch

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healthmatch-pty

- Industry: Healthcare IT
- Headquarters: Sydney, Australia
- Website: www.healthmatch.io
- Total disclosed funding: $25M
- Latest round: Series C (Sep 11, 2022)
- Investors on record: 8

## About

HealthMatch is a technology company that connects patients with clinical trials, facilitating efficient access to innovative medical treatments for those seeking new therapeutic options.Founded in 2017, HealthMatch Pty Ltd. is based in Sydney, Australia, and specializes in matching patients with clinical trials. The company has raised a total of AUD 10.000 mn across multiple funding rounds, with the most recent funding round being a Series C that occurred on September 11, 2022, led by Folklore Ventures with participation from Square Peg. The co-founders include Arran Schlosberg, Kjelt Van Den Hazel, and Manuri Gunawardena, who currently serves as CEO.HealthMatch specializes in connecting patients with clinical trials through its core platform, which facilitates an efficient match between individuals seeking innovative medical treatments and trial sites looking for participants. The primary service offered is an online portal that allows patients to explore available clinical trials based on their specific health needs and conditions. This service addresses the challenge of patient recruitment for clinical studies, thereby accelerating the development of new therapies. HealthMatch's client base primarily consists of patients eager to find potential treatment options and research sites or sponsors seeking to enhance their participant recruitment efforts. The platform operates across multiple geographical markets, including the United States, Canada, the United Kingdom, and Australia, broadening access to clinical trial opportunities for diverse populations.HealthMatch generates revenue through a partnership model with clinical trial sites and sponsors, offering subscription-based access to its platform for enhanced visibility and recruitment capabilities. Clients, including pharmaceutical companies and research organizations, typically enter into contractual agreements that outline the terms of service and associated fees for utilizing HealthMatch's matching services. The revenue structure is based on the number of trials a client wishes to promote and the level of analytics or insights they require from the platform. Flagship services include the Unify Platform and the SCOPE 2025 Trial Site Portal, which provide comprehensive tools for trial management and patient engagement. Each service is tailored to meet the distinct needs of its clients, thus fostering a robust ecosystem for clinical research transactions.In September 2022, HealthMatch Pty Ltd. raised AUD 10.000 mn in Series C funding led by returning investor Folklore Ventures, with participation from Square Peg. The company plans to utilize this funding to increase staffing and expand its platform across the United States, aiming to enhance service delivery and reach a broader patient population. Additionally, HealthMatch is focused on the design and launch of new products to improve user experience and engagement in trial participation.

## Funding rounds

- Series C, Sep 11, 2022, $6.8M — Square Peg, Folklore Ventures
- Series B, Dec 11, 2020, $14M — Square Peg, Folklore Ventures, January Capital, Athletic Ventures, Turnbull Family Office, Bobby & Tamara Super Pty Ltd, Dalit Pty Ltd, Md Radiology Pty Ltd
- Series A, Nov 7, 2019, $4.1M — Square Peg, Folklore Ventures, Md Radiology Pty Ltd

## Investors

- Square Peg (https://capitalatlas.ai/funds/square-peg) — Series A, Series B, Series C
- Folklore Ventures (https://capitalatlas.ai/funds/folklore-ventures) — Series A, Series B, Series C
- Md Radiology Pty Ltd — Series A, Series B
- January Capital (https://capitalatlas.ai/funds/january-capital) — Series B
- Athletic Ventures (https://capitalatlas.ai/funds/athletic-ventures) — Series B
- Turnbull Family Office — Series B
- Bobby & Tamara Super Pty Ltd — Series B
- Dalit Pty Ltd — Series B